REVIEW ARTICLE

 

Osteosarcoma: Pathology, staging and management

 

 

DJ van der Spuy^I; GJ Vlok^II

^IMBChB (Stell); Orthopaedic Surgery Registrar, University of Stellenbosch
^IIMBChB, MMed(Orth), FC(Orth) SA; Professor and Head: Dept of Orthopaedic Surgery, Tygerberg Hospital/University of Stellenbosch

Correspondence

 

“Full text available only in PDF format”

 

 

References

1. Gibbs CP, Weber K, Scarborough T. Malignant Bone Tumours; J Bone Joint Surg 2001;83A:1728-44.         [ Links ]

2. Dahlin DC, Coventry MB. Osteosarcoma, a study of 600 cases. J Bone Joint Surg 1967;49A:101-10.         [ Links ]

3. World LE, Unni KK, Beaubout JW, Sim FH, Dahlin DC. Dedifferentiated parosteal osteosarcoma. J Bone Joint Surg 1984;66A:53-9.         [ Links ]

4. Sheth DS, Yasko AW, Raymond AK, Ayala AG, Carrasco CH, Benjamin RS, Jaffe N, Murray JA. Conventional and dedifferentiated parosteal osteosarcoma: Diagnosis, treatment and outcome. Cancer 1996;78(10):2136-45.         [ Links ]

5. Okada K, Frassica FJ, Sim FH, Beabout JW, Bond JR, Unni KK. Parosteal osteosarcoma. A clinicopathological study. J Bone Joint Surg [Am] 1994;76:366-78.

6. Malkin D, Chilton-MacNeill S, Meister LA, et al. Tissue specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Oncogene 2001;20:4441.         [ Links ]

7. Carbone M, Rizzo Procopio A, et al. SV40-like sequences in human bone tumours. Oncogene 1996;13:527.         [ Links ]

8. Porter DE, Holder ST, Steel CM, et al. A significant proportion of the patients with osteosarcoma may belong to the Li-Fraumeni cancer families. J Bone Joint Surg [Br] 74-B:883-6.

9. Cumin I, Cohen JY, David A, et al. Rothmund-Thomson syndrome and osteosarcoma. Med PediatrOncol 1996;26:414.         [ Links ]

10. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg [Am] 200l;82:667-74.

11. Jaffe N, Spears R, Efthekari F, Robertson R, Congir A, Takaue Y, Carrasco H, Wallace S, Agala A, Raymond K, et al. Pathological fractures in osteosarcoma. Impact of chemotherapy on primary tumor and survival. Cancer 1987;59:701-9.         [ Links ]

12. Bloem JL, Kroon HM. Osseous lesions. Radiol Clin North Am 1993;31:261-78.         [ Links ]

13. Hudson TM, Enneking WF, et al. Magnetic resonance imaging of bone and soft tissue tumors: Early experience in 31 patients compared with computed tomography. Skeletal Radiol 1983;10:137-46.         [ Links ]

14. Pass HI, Dwyer A, Makuch R, et al. Detection of pulmonary metastasis in patients with osteogenic osteosarcomas: The superiority of CT scans in comparison to conventional tomograms using dynamic analysis. J Clin Oncol 1985;3:1261-5.         [ Links ]

15. Chew FS, Hudson TM. Radionuclide bone scanning of osteosarcoma: Falsely extended uptake patterns. Am J Roentgenol 1982;139:49-54.         [ Links ]

16. Kole AC, Nieweg OE, van Ginkel RJ, et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose. Ann Surg Oncol 1997;4:57-63.         [ Links ]

17. Early JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 1998;39:250-4.         [ Links ]

18. Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990;170:223-30.         [ Links ]

19. Panuel M, Gentet JC, Scheiner C, et al. Physeal and epiphyseal extent of primary malignant bone tumour in childhood: Correlation of preoperative MRI and the pathological examination. Pediatr Radiol 1993;23:421-4.         [ Links ]

20. Dickson GR, Shirodria PV, Kanis JA, et al. Familial expansile osteolysis: a morphological, histomorphometric and serological study. Bone 1991;12:331-8.         [ Links ]

21. Greenspan A, Remagen W. Differential diagnosis of tumors and tumor-like lesions of bones and joints. Lippincott-Raven & Williams 1998;59-117. Philadelphia        [ Links ]

22. Unni KK, Dahlin DG, Beaubout JW. Periosteal osteogenic osteosarcoma. Cancer 1976;37:2476-85.         [ Links ]

23. Enneking WF, Spanier SS, Goodman MA. Current concept review: Surgical staging of musculoskeletal sarcoma. J Bone Joint Surg 1982;62A:1027-30.         [ Links ]

24. Greene FL, Page DL, Flemming FD: Editors. American Joint Committee on cancer: Cancer staging manual. 6^th edition New York: Springer; 2002.         [ Links ]

25. Kim MS, Lee S, Cho WH, Song WS, Koh J, Lee JA, Yoo JY, Jeon D. Initial tumor size predicts histological response and survival in localised osteosarcoma patients. J Surg Oncol 2008;97:456-61.         [ Links ]

26. Campanacci M, Cervellati G. Osteosarcoma: A review of 345 cases. Ital J Orthop Traumatol 1975;1:5-22.         [ Links ]

27. Dahlin DC. Osteosarcoma of bone and a consideration of prognostic variables. Cancer Treat Rep 1978;62:189.         [ Links ]

28. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high grade osteosarcoma of the extremity: Updated results of the multi-institutional osteosarcoma study. Clin Orthop Relat Res 1991:8.         [ Links ]

29. McKenna RJ, Schwinn CP, Soong KY, et al. Sarcomata of the osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcoma arising in abnormal bone): An analysis of 522 cases. J Bone Joint Surg [Am] 1966;48:1-26.

30. Jaffe N, Frei E III, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. Eng J Med 1997;291(19):994-7.         [ Links ]

31. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314(25):1600-6.         [ Links ]

32. Winkler K, Beron G, Delling G, Heise U, kabisch H, Purfurts C, Berger J, Ritter J, Jurgens H, Gerein V, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy on histological tumor response. J Clin Oncol 1988;6:329-37.         [ Links ]

33. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathological aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977;101:14-8.         [ Links ]

34. Anderson PM, Wiseman GA, Erlandson L. Gemcitabine radiosensitization after high dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 2005;11(19 Pt1):6895-900.         [ Links ]

35. Kindler HL. The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer 2002;95(4 Suppl.):928-32.         [ Links ]

36. Jeys LM, Grimer RJ, Carter SR, Tillman RM, Abudu A. Postoperative infection and increased survival in osteosarcoma patients: are they associated? Ann Surg Oncol 2007;14(10):2887-95.         [ Links ]

37. Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol 1991;9(2):259-67.         [ Links ]

38. Meyer PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - report from the Children's Oncology Group. J Cancer 2008;26(4):633-8.         [ Links ]

39. Armitage JO. Emerging applications of recombinant human-granulocyte-macrophage colony-stimulating factor. Blood 1988;92(12):4491-508.         [ Links ]

40. Kumar R, Yoneda J, Fidler IJ, Dong Z. GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice. J Leukoc Biol 1999;65(1):102-8.         [ Links ]

41. Siegel J, Pressey JG. Current concepts on the surgical and medical management of osteosarcoma. Expert Rev Anticancer Ther 2008;8(8):1257-69.         [ Links ]

42. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erB-2 correlates with survival in osteosarcoma. J Clin Oncol 1988;17(9):2781-8.         [ Links ]

43. Muraro M, Mereuta OM, Carraro F, Madon E, Fagioli F. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. Cell Immuno 2007;249(2):63-72.         [ Links ]

44. Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2003;21(2):334-41.         [ Links ]

45. Campanacci M, Laus M. Local recurrence after amputation for osteosarcoma. J Bone Joint Surg [Br] 1980;2-B:201-7.

46. Campanacci M, Bacci G, Payani P, Giunti A. Multiple drug chemotherapy for the primary treatment of osteosarcoma of the extremities. J Bone Joint Surg [Br] 1980;62-B:93-101.

47. Simon MA, Aschliman MA, Thomas N, Mankin HJ. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg [ Am] 1986;68:1331-7.

48. Springfield DS, Schmidt R, Graham-Pole J, Marcus RB Jr, Spanier SS, Enneking WF. Surgical treatment of osteosarcoma. J Bone Surg [Am] 1980;70:1124-30.

49. Rougraff BT, Simon MA, Kreisl JS, Greenberg DB, Mankin HJ. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long term oncological, functional, and quality-of-life study. J Bone Joint Surg [Am] 1994;76:649-56.

50. Kagen LB. Use of denial in adolescents with bone cancer. Health Soc Work 1976;1:70-87.         [ Links ]

51. Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC. Pathological fractures in osteosarcoma: Prognostic importance and treatment implications. J Bone Joint Surg [ Am] 2002;84-A:49-57.

52. Cammisa FP Jr, Glasser DB, Otis JC, et al. The van Nes tibial rotationplasty. A functionally viable reconstructive procedure in children who have a tumor of the distal end of the femur. J Bone Joint Surg [Am] 1990;72:1541-7.

53. Meyers PA, Heller G, Healey JH, Huvos A, Appelwhite A, Sun M, La Quaglia M. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993;11:449-53.         [ Links ]

54. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: A critical review. Clin Oncol 1994;12:423-31.         [ Links ]

 

 

Correspondence:
Dr DJ van der Spuy
Dept of Orthopaedic Surgery
PO Box 19063
Tygerberg
7505
Tel: +27 21 938-9266

 

 

The content of this article is the sole work of the author. No benefits of any form have been derived from any commercial party related directly or indirectly to the subject of this article.